Plain-English translation of NCT07027345 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new topical gel called TolaSure to see if it can help treat epidermolysis bullosa simplex (EBS), a genetic condition that causes painful blisters and skin damage. Half of the participants will receive the new medication while half receive a placebo (inactive gel), and neither patients nor doctors will know which is which. The study will track how well the treatment works and whether it is safe.
Epidermolysis bullosa simplex causes recurring blisters and skin breakdown that can be painful and limit daily activities. There are limited treatment options available, so researchers are testing whether this new topical medication might help reduce blistering and help the skin heal better.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will apply the study gel (or placebo) once daily to the affected skin areas for 2 months. The treatment area depends on your type of EBS—for some patients it's the feet, and for others it may be the legs or torso. You will have regular visits with the study team so they can examine your skin, track how many blisters you have, and watch for any side effects. The study team will also take photos or measurements of the treated areas to compare over time.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States